Epidemiology and clinical course of vulvar melanoma: experience of the Republic of Bashkortostan

Cover Page


In 2019, melanoma affects 66.9 per 100,000 populations in the Russian Federation, which was higher than 44.5 in 2009. Vulvar melanoma is one of the rare localizations of malignant tumors. Its disease course and prevalence differ from those of skin melanoma. Given the rarity of this localization, no large studies have been published in the Russian Federation.

Objective. This study aimed to study the clinical course and prevalence of vulvar melanoma in the Republic of Bashkortostan.

Materials and methods. A retrospective analysis of the clinical course of malignant tumors of the external genital organs was carried out in 324 patients within a 5-year period. Vulvar melanoma was diagnosed in 23 cases, which accounted for 6.5% of the total number of patients with malignant neoplasms of the female external genital organs. The clinical course and medical data in 23 patients diagnosed with vulvar melanoma were evaluated. The disease stage, characteristics of the clinical course, and presence of BRAF and c-KIT mutations were assessed. In the Republic of Bashkortostan, the incidence of vulvar melanoma was estimated based on the data of the Republican Clinical Oncological Dispensary.

Results. Within 5 years, 23 patients were diagnosed with vulvar melanoma, which is a very small proportion relative the total number of patients with cancer. Difficulties in determining the scope of adequate surgical treatment and presence of prognostic factors define the prognosis of the disease. Most of the patients at the first stage of the disease received surgical treatment. The scope of surgical treatment was based on the localization of the primary tumor and the presence of metastases in regional lymph nodes.

Conclusion. Vulvar melanoma is a rare and aggressive malignant tumor. In the Republic of Bashkortostan, as well as in the Russian Federation, no register has been established for this localization. In view of the anatomical features of this zone, the tumor develops more aggressively and characterized by early lymphogenous metastasis. In patients with fairly young age, an aggressive disease course requires special attention.

Full Text

Restricted Access

About the authors

Konstantin V. Menshikov

Bashkir State Medical University

Author for correspondence.
Email: kmenshikov80@bk.ru
ORCID iD: 0000-0003-3734-2779

MD, PhD, oncologist of the Department of Chemotherapy of the Republican Clinical Oncological Dispensary, 450054, Ufa, Russian Federation, Associate Professor of the Department of Oncology with courses oncology and pathological anatomy, Bashkir State Medical University, 450008, Ufa, Russian Federation

Russian Federation, 450008, Ufa


  1. Kaprin AD, red. The state of cancer care for the population of Russia in 2019. M.: MNIOI im. P.A. Gertsena; 2020;239. (In Russ).
  2. Sturgeon SR, Brinton LA, Devesa SS, Kurman RJ. In situ and invasive vulvar cancer incidence trends. Am J Obstet Gynecol. 1992;166(5):1482–5. doi: 10.1016/0002-9378(92)91623-i.
  3. Chhabra S, Bhavani M, Deshpande A. Trends of vulvar cancer. J Obstet Gynaecol. 2014;34(2):34:165–168. doi: 10.3109/01443615.2013.834310.
  4. Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol. 2008;108(3):577–583. doi: 10.1016/j.ygyno.2007.11.011.
  5. Koh W-J, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, et al. Vulvar cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(1):92–120. doi: 10.6004/jnccn.2017.0008.
  6. Coit D, Thompson J, Algazi A, Andtbacka R, Bichakjian C, Carson W 3rd, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(4):1528–64.
  7. Wong SL, Faries MB, Kennedy EB, et al. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018;25:356–377. doi: 10.1245/s10434-017-6267-7.
  8. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26 (Supplement 5): v126–v132, 2015. doi: 10.1093/annonc/mdv297
  9. AWMF. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, V 3.1. AWMF; 2018. https ://www.awmf.org. Accessed 23 Oct 2019. doi: 10.1007/s00772-018-0452-2.
  10. Hou JY, Baptiste C, Hombalegowda RB, Tergas AI, Feldman R, Jones NL, et al. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer. 2017;123(8):1333–44. doi: 10.1002/cncr.30473.
  11. Saglam O, Messina J, Naqvi SMH, Teer JK, Lee J, Zhang Y, et al. Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation; a single-institution experience. Melanoma Res. 2018Dec;28(6):586–591. doi: 10.1097/CMR.0000000000000480.
  12. Rouzbahman M, Kamel-Reid S, Al Habeeb A, Butler M, Dodge J, Laframboise S, et al. Malignant melanoma of vulva and vagina. J Low Genit Tract Dis. 2015 Oct;19(4):350–3. doi: 10.1097/LGT.0000000000000142.
  13. Wohlmuth C, Wohlmuth-Wieser I, May T, Vicus D, Lilian T, Gien, Laframboise S. Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. American Journal of Clinical Dermatology. 2020;(21):285–295. doi: 10.1007/s40257-019-00487-x.
  14. Sinasac SE, Petrella TM, Rouzbahman M, Sade S, Ghazarian D, Vicus D. Melanoma of the vulva and vagina: surgical management and outcomes based on a clinicopathologic review of 68 cases. J Obstet Gynaecol Can. 2019;(41):762–71. doi: 10.1016/j.jogc.2018.07.011
  15. Phillips GL, Bundy BN, Okagaki T, Kucera PR, Stehman FB. Malignant melanoma of the vulva treated by radical hemivulvectomy: a prospective study of the gynecologic oncology group. Cancer. 1994;73(10):2626–32. doi: 10.1002/1097-0142(19940515)73:10<2626::AID-CNCR2820 731026>3.0.CO; 2-U.
  16. Trimble EL, Lewis JL, Williams LL, Curtin JP, Chapman D, Woodruff JM, et al. Management of vulvar melanoma. Gynecol Oncol. 1992;45(3):254–8. doi: 10.1016/0090-8258(92)90300-8.
  17. Verschraegen CF, Benjapibal M, Supakarapongkul W, Levy LB, Ross M, Atkinson EN, et al. Vulvar melanoma at the M.D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer. 2001;11(5):359–64. doi: 10.1046/j.1525-1438.2001.01043.x.
  18. Räber G, Mempel V, Jackisch C, Hundeiker M, Heinecke A, Kürzl R, et al. Malignant melanoma of the vulva: report of 89 patients. Cancer. 1996;78(11):2353–8. doi: 10.1002/(sici)1097-0142(19961201)78:11<2353::aid-cncr13>3.0.co;2-#.

Supplementary files

Supplementary Files
1. Fig. 1. The number of patients diagnosed with malignant neoplasms of the vulva in the Republic of Bashkortostan in the period from 2015 to 2019

Download (87KB)
2. Fig. 2. А – Distribution of patients according to T criterion. B – according to N criterion. C – according to M

Download (111KB)
3. Fig. 3. Melanoma of the vulva. When examining the postoperative material, the T1B stage was established

Download (261KB)
4. Fig. 4. The presence of a mutation in the BRAF gene of the V600E type

Download (69KB)



Abstract: 124

PDF (Russian): 2

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies